24 results
Thumbnail

D2.283 - Beyond the skin. A rare case of contact angioedema due to Methylisothiazolinone

Thumbnail

D2.292 - Epinephrine Nasal Powder - a sustainable and reliable option for the treatment of anaphylaxis

Thumbnail

D2.293 - Assessment of the Efficacy of Specific Immunotherapy After a Long Break in Asthmatic Patients

Thumbnail

D2.278 - National Survey on Perioperative Hypersensitivity Reactions: Evaluating Practices and Challenges in Spanish Hospitals

Thumbnail

D2.279 - In an emergency, can YOU really give that adrenaline pen? – the need for structured, further and improved training in Ireland

Thumbnail

D2.282 - IgE-mediated anaphylaxis to quinine confirmed with a basophil activation test

Thumbnail

D2.284 - Eat the fruit, do not swallow the seed: A rare case of Cucurbitaceae allergy causing anaphylaxis

Thumbnail

D2.286 - A case of prawn induced FDEIA

Thumbnail

D2.287 - Evaluation of NSAID Hypersensitivity in Children: A Retrospective Analysis

Thumbnail

D2.288 - Idursulfase Hypersensitivity Reactions: Unpacking Immunological Mechanisms Beyond Clinical Manifestations

Thumbnail

D2.289 - A Cardiovascular Enigma in the Emergency Room

Thumbnail

D2.290 - Allergens involved in a case report of anaphylaxis to ginger (Zingiber officinale), a very rare but severe allergy

Thumbnail

D2.291 - The level of knowledge of adolescent and young adults about food allergies and anaphylaxis: Key information that can save lives - a pilot study

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series